Young, David, Rahmany, Sohail, Taylor, Deborah, Davis, Emma, Colwill, Michael, Mehta, Sonia Kalyanji, Campbell, Roisin, Hazel, Karl, Sethi-Arora, Karishma, Ritchie, Susan, Heinson, Ashley I, Moyses, Helen, Bodger, Keith, Johnston, Emma, Hicks, Lucy, Dhar, Anjan, Limdi, Jimmy, Cooney, Rachel, Seenan, John Paul, Patel, Kamal, Walsh, Alissa and Cummings, Fraser (2025) Real-world assessment of effectiveness and safety of filgotinib in 286 patients with ulcerative colitis in 9 UK centres. Drugs in Context, 14. (doi:10.7573/dic.2024-11-1).
Abstract
Background: filgotinib, an oral Janus kinase 1 preferential inhibitor, has been shown to be an effective treatment for ulcerative colitis (UC) in pre-registration studies. We aimed to describe the treatment population, effectiveness and safety of filgotinib in a real-world cohort of patients with UC.
Methods: a retrospective observational cohort evaluation was conducted across nine UK inflammatory bowel disease centres. Baseline demographic and clinical data, clinical disease activity scores, endoscopic activity indices, and biomarkers (C-reactive protein and faecal calprotectin) were collected at baseline, at 8–12 weeks after initiation (post-induction) and during maintenance (the most recent review) where available. Effectiveness outcomes were assessed in patients with combined clinical disease activity and objective evidence of inflammation at filgotinib initiation.
Results: data were analysed for a total of 286 patients with a median follow-up time of 229 (IQR 113–324) days. The median age at filgotinib initiation was 38 (IQR 27–51) years, 64% were men and median disease duration was 5.1 (IQR 1.9–10.5) years; 56% had previous exposure to advanced therapies (biologics and small molecule) and 6% previously received tofacitinib. At the post-induction review, clinical response and remission were achieved in 65% and 51% of patients, respectively. There was a reduction in biomarkers and 78% of patients using corticosteroids at baseline were steroid-free. Persistence on filgotinib at 12 months was 66%. Adverse events were recorded in 30 patients with 8 patients discontinuing filgotinib as a result of an adverse event.
Conclusions: in a large real-world cohort of patients with UC, filgotinib appears to be effective and well-tolerated.
More information
Identifiers
Catalogue record
Export record
Altmetrics
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.